Vanguard Personalized Indexing Management LLC Sells 2,080 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Vanguard Personalized Indexing Management LLC decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 12.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,189 shares of the medical equipment provider’s stock after selling 2,080 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Zimmer Biomet were worth $1,619,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tredje AP fonden raised its stake in Zimmer Biomet by 172.5% during the second quarter. Tredje AP fonden now owns 32,505 shares of the medical equipment provider’s stock worth $3,528,000 after buying an additional 20,576 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. raised its position in shares of Zimmer Biomet by 10.2% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 3,786 shares of the medical equipment provider’s stock worth $411,000 after acquiring an additional 351 shares in the last quarter. E Fund Management Co. Ltd. raised its position in shares of Zimmer Biomet by 10.9% in the 2nd quarter. E Fund Management Co. Ltd. now owns 1,917 shares of the medical equipment provider’s stock worth $208,000 after acquiring an additional 189 shares in the last quarter. Sofinnova Investments Inc. bought a new stake in shares of Zimmer Biomet during the 2nd quarter valued at about $1,154,000. Finally, Virtu Financial LLC bought a new stake in shares of Zimmer Biomet during the 2nd quarter valued at about $2,557,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

ZBH has been the topic of several recent analyst reports. Citigroup dropped their price target on Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 10th. JPMorgan Chase & Co. dropped their target price on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a research report on Monday, September 16th. Canaccord Genuity Group reduced their price target on shares of Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, September 10th. Evercore ISI reiterated an “in-line” rating and set a $113.00 price objective on shares of Zimmer Biomet in a report on Thursday, September 5th. Finally, Robert W. Baird reduced their target price on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $125.17.

Zimmer Biomet Trading Up 0.1 %

NYSE ZBH opened at $106.42 on Friday. The company has a current ratio of 1.29, a quick ratio of 0.63 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $21.89 billion, a P/E ratio of 23.03, a PEG ratio of 1.96 and a beta of 1.02. The business has a fifty day simple moving average of $109.83 and a 200 day simple moving average of $115.46. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. During the same period last year, the firm earned $1.82 earnings per share. The firm’s revenue was up 3.9% on a year-over-year basis. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.02 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date is Monday, September 30th. Zimmer Biomet’s payout ratio is 20.78%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.